Population Screening Global Market Report 2023 – By Product (Hardware Equipment, Testing Or Lab, Analytics Or Interpretation), By Gender (Male, Female), By Age (Ages Less Than 15, 15-65, Ages 65 And Above), By Business (Hospitals, Research Institutes, Diagnostic Labs) – Market Size, Trends, And Global Forecast 2023-2032

Cellular health screening refers to a type of medical examination that assesses inflammatory conditions by taking samples from a person's cells, tissues, and organs. This screening can be performed through various methods, including blood tests, urine tests, and imaging tests. This screening is primarily utilized for fast analysis of health at the cellular level. The main test types for cellular health screening are single-test panels, telomere tests, oxidative stress tests, inflammation tests, heavy metals tests, and multi-test panels. Single-test panels are diagnostic tests that assess a specific aspect of a person's health, often focusing on a single biomarker or physiological function. The various types of samples included are blood, saliva, serum, and urine, which can be collected at various collection sites, such as homes, offices, hospitals, and diagnostic labs. The global cellular health screening market is segmented - 1) By Test Type: Single Test Panels, Telomere Tests, Oxidative Stress Tests, Inflammation Tests, Heavy Metals Tests, Multi-test Panels 2) By Sample Type: Blood, Saliva, Serum, Urine 3) By Collection Site: Home, Office, Hospital, Diagnostic Labs The global cellular health screening market size is expected to grow from $2.69 billion in 2022 to $3.01 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cellular health screening market size is expected to reach $4.55 billion in 2027 at a CAGR of 10.8%. The rise in chronic diseases is expected to propel the growth of the cellular health screening market going forward. Chronic diseases are medical problems that last for a long time and necessitate continuing management and care. Cellular health screening can help prevent disease or reduce the severity of illness by detecting people who have chronic diseases due to factors such as genetic predisposition, lifestyle choices, environmental conditions, and underlying health issues. For instance, in October 2022, according to the Centers for Disease Control and Prevention, a US-based intergovernmental organization, the most common type of heart disease was coronary heart disease, which affected around 20.1 million people aged 20 and older. Every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in the United States experience a heart attack each year. Furthermore, in January 2023, according to the National Library of Medicine, a US-based biomedical library operated by the federal government, the number of people in the USA aged 50 and older who have at least one chronic condition is predicted to rise by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Therefore, the rise in chronic diseases is driving the growth of the cellular health screening market. Major players in the cellular health screening market are Bio-Reference Laboratories Inc., Laboratory Corporation, Quest Diagnostics, Cell Science Systems, Genova Diagnostics (GDX), Immundiagnostik AG, Life Length, Repeat Diagnostics Inc., Segterra Inc., SpectraCell Laboratories Inc., Telomere Diagnostics Inc., Zimetry LLC, Cleveland Heartlab Inc., Agilent Technologies Inc., DNA Labs India, and Bloom Diagnostics GmbH. Technological advancements are a key trend gaining popularity in the cellular health screening market. Companies operating in the cellular health screening market are adopting new technologies to sustain their position in the market. For instance, in November 2020, Axion BioSystems, a US-based biotechnology company, launched the Maestro ZHT, a high-throughput live-cell screening platform. The adaptable Maestro ZHT will monitor cells continually, without labels or dyes, whether comparing immune cell-mediated killing by CRISPR-derived CAR-T cells, vaccine effectiveness, or chemotherapies against patient-derived tumor cells. It has robust turn-key software that offers regulatory compliance features to satisfy FDA 21 CFR Part 11 data traceability standards. It allows users to quantify kinetic cellular responses and remotely monitor trials. In August 2021, Illumina Inc., a US-based biotechnology company, acquired Grail Inc. for an undisclosed sum. This acquisition helped Illumina enter the cancer screening market and expand its capabilities in genomics and precision medicine. GRAIL Inc. is a US-based healthcare company focused on developing blood tests for early cancer detection that operates in the cellular health screening market. North America was the largest region in the cellular health screening market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global cellular health screening market report during the forecast period. The regions covered in the global cellular health screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cellular health screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cellular health screening market includes revenues earned by entities by assessing inflammatory conditions, such as allergies, asthma, arthritis, and autoimmune conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cellular health screening market research report is one of a series of new reports from The Business Research Company that provides cellular health screening market statistics, including cellular health screening industry global market size, regional shares, competitors with a cellular health screening market share, detailed cellular health screening market segments, market trends and opportunities, and any further data you may need to thrive in the cellular health screening industry. This cellular health screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blood screening refers to a method of screening blood, plasma, or blood components for transfusion or use in blood products. It is used to screen for antibodies or tumour markers, to seek for disease-causing substances or symptoms, or to evaluate treatment effectiveness. The main product of blood screening are reagents and kits, instruments, software and services. Reagents refer to a substance or compound that can facilitate a reaction used in detecting or measuring a component or in preparing a product due to its chemical or biological activity, whereas kits are test kits that can be used in a lab setting or out in the field to find specific compounds in a sample. The technology included nucleic acid testing, enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assays and next-generation sequencing (NGS), and involves blood banks, diagnostic centers and pathology labs, hospitals, clinics and ambulatory surgical centers (ASCs). The global blood screening market is segmented - 1) By Product: Reagents and Kits, Instruments, Software and Services 2) By Technology: Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assays, Next-Generation Sequencing (NGS) 3) By End User: Blood Banks, Diagnostic Centers and Pathology Labs, Hospitals, Clinics, Ambulatory Surgical Centers (ASCs) The global blood screening market size is expected to grow from $2.65 billion in 2022 to $2.92 billion in 2023 at a compound annual growth rate (CAGR) of 10.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global blood screening market size is expected to reach $4.24 billion in 2027 at a CAGR of 9.7%. The increasing prevalence of infectious diseases is expected to propel the growth of the blood screening market going forward. Blood is commonly analysed for symptoms of illness by looking for a specific antibody generated against the infectious agent, which aids the medical practitioner in treating infectious diseases and preventing further transmission of infection in patients and disease spread from one to one. For instance, in October 2022, according to the fact sheet published by World Health Organization (WHO), a US-based government agency, approximately 1.6 million persons worldwide passed away from tuberculosis in 2021 (including 187 000 people with HIV). Additionally, in December 2022, according to the fact sheet published by World Health Organization, malaria cases increased from 227 million in 2019 to 241 million, and around 6,27,000 people were predicted to die from malaria in 2020, an increase of 69,000 fatalities over 2019. Therefore, the increase in the prevalence of infectious diseases is driving the growth of the blood screening market. Major players in the blood screening market are Abbott Laboratories, Grifols S.A, Becton Dickinson and Company, F. Hoffmann-La Roche AG, bioMérieux SA, Bio-Rad Laboratories Inc., Thermo Fisher Scientific, Ortho Clinical Diagnostics, Beckman Coulter Inc., Siemens Healthineers, GE HealthCare, DiaSorin, Merck KGaA, PerkinElmer Inc., and Bio-Techne Corporation. Product innovation is a key trend gaining popularity in the blood screening market. Major companies operating in the market are focused on research and development for product innovations to sustain their position in the market. For instance, in November 2021, Intuity Medical, Inc., a US-based company operating in diabetes management, introduced the POGO system, an automatic blood glucose monitoring device. The Pogo system utilizes 10-test cartridge technology in which lances, collects, and analyses blood from the finger all at once and displays results in a four-second countdown, eliminating the need to carry additional test strips and lancets. It provides a straightforward blood glucose testing experience than a conventional blood glucose metre. In December 2021, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical and diagnostic company, acquired TIB Molbiol Group for an undisclosed amount. Through this acquisition, F. Hoffmann-La Roche AG aims to enhance its capabilities for the rapid development of assays for emerging pathogens and potential health threats, such as infectious diseases. TIB Molbiol Group is a Germany-based diagnostics company that performs blood screening for testing, life science research and medical diagnostics. North America was the largest region in the blood screening market in 2022. The regions covered in the global blood screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the blood screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The blood screening market consists of revenues earned by entities by providing transcription mediated amplification (TMA) and real-time PCR. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood screening market also includes sales of analyzer, photo colorimeter, flame photometer, hemoglobin meter, blood roller mixer, dry bath incubators, and differential blood counter. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The blood screening market research report is one of a series of new reports from The Business Research Company that provides blood screening market statistics, including blood screening industry global market size, regional shares, competitors with a blood screening market share, detailed blood screening market segments, market trends and opportunities, and any further data you may need to thrive in the blood screening industry. This blood screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Carrier screening refers to a type of genetic test that can determine if there is a gene that causes certain genetic illnesses. The carrier screening is used to identify people who have one copy of a gene mutation that produces a hereditary illness when two copies are present. The main types of carrier screening are expanded carrier screening and targeted disease carrier screening. Expanded carrier screening provides carrier screening for multiple autosomal and X-linked recessive disorders, facilitated by new genetic testing technologies, and allows testing of individuals regardless of ancestry or geographic origin. The products and services are service and product. The medical conditions are pulmonary conditions, hematological conditions, neurological conditions, and other medical conditions. The technologies involved DNA sequencing, polymerase chain reaction, microarrays, and other technologies. The various end users included hospitals, reference laboratories, physician offices and clinics, and other end users. The global carrier screening market is segmented - 1) By Type: Expanded Carrier Screening, Targeted Disease Carrier Screening 2) By Product and Service: Service, Product 3) By Medical Condition: Pulmonary Conditions, Hematological Conditions, Neurological Conditions, Other Medical Conditions 4) By Technology: DNA Sequencing, Polymerase Chain Reaction, Microarrays, Other Technologies 5) By End User: Hospitals, Reference Laboratories, Physician Offices and Clinics, Other End Users The global carrier screening market size is expected to grow from $2.03 billion in 2022 to $2.38 billion in 2023 at a compound annual growth rate (CAGR) of 17.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global carrier screening is expected to grow to $4.30 billion in 2027 at a CAGR of 15.9%. An increase in fetal chromosomal abnormalities and genetic disorders is expected to propel the growth of the carrier screening market going forward. Fetal chromosomal abnormalities refer to a fetus with an abnormal number of chromosomes, an abnormal quantity of DNA inside a chromosome. Prenatal testing for chromosomal abnormalities is intended to provide an accurate assessment of a patient's risk of carrying a fetus with a chromosomal disorder. For instance, in February 2022, according to estimates by the World Health Organization, a Switzerland-based global health agency, birth defects cause 240 000 newborns to pass away in the first 28 days of life each year. An additional 170,000 children between the ages of 1 month and 5 years die as a result of birth defects. Moreover, in March 2022, according to an article published by the Government of United Nations, Down syndrome is estimated to affect 1 in 1,000 to 1 in 1,100 live births worldwide. Every year, between 3,000 and 5,000 children are born with this chromosome disorder. Therefore, an increase in fetal chromosomal abnormalities and genetic disorders is driving the growth of the carrier screening market. Major players in the carrier screening market are Invitae Corporation, Fulgent Genetics Inc., Illumina Inc., Sema4 Holdings Corporation, Natera Inc., Laboratory Corporation of America Holdings, Centogene NV, Thermo Fisher Scientific Inc., Myriad Genetics Inc., Eurofins Scientific SE, OPKO Health Inc., Quest Diagnostics Inc., Luminex Corporation, BGI Genomics, Gene by Gene, OME Care, MedGenome Inc., and Otogenetics Corporation. Technological advancements are a key trend gaining popularity in the carrier screening market. Major companies operating in the carrier screening market are focused on developing new technological solutions to strengthen their position. For instance, in July 2020, NIPD Genetics, a Cyprus-based biotechnology company, released Adventia, a broader carrier screening test for anyone or a couple interested in learning if they are carriers of a genetic disease. Adventia is a safe, reliable, and exclusive test for up to 229 X-linked and autosomal recessive illnesses that offer healthcare professionals and individuals significant genetic insight and information about their reproductive possibilities. Adventia consists of three panels: (a) the Focus Panels, which give the option to test one of six moderate-to-severe, high-frequency monogenic diseases; (b) the Guidelines-Based Panel, which includes all diseases in the Focus Panels and tests for 19 diseases with high carrier frequency; and (c) the Comprehensive Panel, which includes all diseases in the Guidelines-Based Panel and tests for a total of 229 diseases with a clearly defined phenotype and high cumulative frequency. In May 2022, Sema4 OpCo Inc., a US-based firm providing patient-focused health intelligence, acquired GeneDx LLC for $623 million. The acquisition is expected to establish Sema4 as one of the biggest and most sophisticated genomic testing companies in the United States and increase its health information database, which will alter patient care and advance therapeutic research. GeneDx LLC is a US-based company operating in analysis for rare disorders and genomic testing. North America was the largest region in the carrier screening market in 2022. Asia-Pacific is expected to be the fastest-growing region in the carrier screening market report during the forecast period. The regions covered in the carrier screening analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the carrier screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and the USA. The carrier screening market includes revenues earned by entities by providing customized panel testing and predesigned panel testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The carrier screening market research report is one of a series of new reports from The Business Research Company that provides carrier screening market statistics, including carrier screening industry global market size, regional shares, competitors with a carrier screening market share, detailed carrier screening market segments, market trends and opportunities, and any further data you may need to thrive in the carrier screening industry. This carrier screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Security screening refers to screening measures that are designed to keep forbidden objects and other hazards out of the sterile area. These security screening and checkpoints protect the locations from any hazardous events, reassuring travelers that they are safe and protecting people and places. The main types of security screening are x-ray systems, metal detectors, explosive detectors, biometric systems and others. The x-ray system refers to threat detection technologies with intelligent and flexible system design. As a consequence, a dark image is created when the majority of the x-rays are absorbed, whereas a brilliant image is created when the majority of the x-rays flow through the object. Mail and parcel, baggage scanning cargo and vehicle inspection, explosives and narcotics have security screening applications. Security screening is used in government buildings, airports, educational institutes, public places, and others. The global security screening market is segmented - 1) By Type: X-Ray System, Metal Detectors, Explosive Detectors, Biometric System, Other Types 2) By Application: Mail And Parcel, Baggage Scanning, Cargo And Vehicle Inspection, Explosives And Narcotics 3) By End-User: Government Buildings, Airports, Educational Institutes, Public Places, Other End-Users The global security screening market size will grow from $9.37 billion in 2022 to $10.13 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the security screening is expected to grow to $14.08 billion in 2027 at a CAGR of 8.6%. The increasing terrorism is expected to propel the growth of the security screening market. Terrorist uses illegal force and violence to achieve a political, economic, religious, or social purpose through fear, compulsion, or intimidation. With these growing unlawful immigration and terrorist acts worldwide, the demand for security screening systems has risen. According to the Global Terrorism Index, there were 5,226 terrorist acts worldwide in March 2022, up from 4,458 in 2020, which is an increase of 17%. Few nations, including Afghanistan, Iraq, and Somalia, are more significantly impacted by terrorism. Therefore, increasing terrorism will drive the security screening market growth. Major players in the security screening market are Smiths Group plc, L-3 Communication Holding Inc., OSI Systems, Magal Security Systems Ltd., Argus Global Pty Ltd., Analogic Corporation, American Science and Engineering Inc., Aware Inc., Digital Barriers plc, Anviz Global Inc., Laxton Group, Implant Sciences Corporation, 3DX-RAY, ADANI Systems, NEC Corporation, Lockheed Martin, Raytheon, Leidos, Thales, Teledyne ICM, Bruker and Nuctech. Technological advancements have emerged as the key trend in the security screening market. Major companies operating in the security screening market are focused on providing technologically advanced solutions to strengthen their market position. These companies are implementing next-generation security screening technologies into their product and services, such as CT scanners, under-vehicle inspection technologies (UVIS), automated screening lanes, facial recognition, millimeter-wave technology, and others to safeguard and prevent prohibited items and other threats to security. For instance, in November 2021, Smith detection, a threat detection and security screening company, collaborates with Microsoft and Heathrow to build an artificial intelligence technology to detect wildlife trafficking. In the initial testing phase, this technique will be used with their existing screening and security infrastructure to combat illegal wildlife trafficking with AI-powered technology. In May 2020, Leidos, a US-based engineering company, acquired L3Harris Technologies’ (“L3Harris”) Security Detection and Automation businesses for approximately $1 billion in cash. With this acquisition, Leidos will continue to broaden the scope and scale of its operations in securing ports and borders, enhancing passenger circulation in future airports, and reinforcing infrastructure for national security and public venues. L3Harris Technologies is a US-based defense and space manufacturing company. North America was the largest region in the security screening market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the security screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the security screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The security screening market includes revenues earned by entities by providing measures preventing illicit and other potential hazards to transportation security from accessing the airport's sterile space. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The security screening market research report is one of a series of new reports from The Business Research Company that provides security screening market statistics, including security screening industry global market size, regional shares, competitors with a security screening market share, detailed security screening market segments, market trends and opportunities, and any further data you may need to thrive in the security screening industry. This security screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug screening is an approach used for drug testing, identified and optimized for clinical trials used in the analysis of blood, urine, hair, or saliva to detect the presence of chemicals and pollutants and other illicit substance left in the body as a result of drug usage. The main types of drug screening products include rapid testing devices, consumables, and others. Rapid testing devices refer to easy-to-use drug screening devices that provide results quicker than the standard traditional laboratory test. The different samples used in drug screening includes oral fluid sample, hair sample, urine sample, breath sample, and others. They are used in drug testing laboratories, workplaces, criminal justice and law enforcement, hospitals, drug treatment centers, individual users, pain management centers, schools & colleges. The global drug screening market is segmented - 1) By Products: Rapid Testing Devices, Consumables, Other Products 2) By Sample Type: Oral Fluid Sample, Hair Sample, Urine Sample, Breath Sample, Other Sample Types 3) By End User: Drug Testing Laboratories, Workplaces, Criminal Justice and Law Enforcement Agencies, Hospitals, Drug Treatment Centers, Individual Users, Pain Management Centers, Schools and Colleges The global drug screening market size grew from $6.62 billion in 2022 to $7.51 billion in 2023 at a compound annual growth rate (CAGR) of 13.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global drug screening is expected to grow to $12.29 billion in 2027 at a CAGR of 13.1%. Growing drug and alcohol consumption is driving the growth of the drug screening market. Drug addiction is a disease that affects a person's brain and behavior, resulting in the inability to control the use of a legal or illegal drug or medication. Substances such as alcohol, marijuana, and nicotine also are considered drugs. As the drug and alcohol addiction increases, the chances of disease are higher which triggers the need for drug screening. For instance, in June 2019 & 2020, according to a report published by the United Nations Office on Drugs and Crime (UNODC), 35 million people globally suffer from drug use disorders and require treatment services. The severity and complexity of the world drug situation are increasing, revealing that the number of people who use drugs is now 30% higher than in 2009. The pandemic effects also ramp up drug risks, as cannabis intake by youth had increased by as much as four times in parts of the world. Therefore, growing drug and alcohol consumption is driving the growth of the drug screening market. Major players in the drug screening market are LabCorp, Quest Diagnostics, Alere, OraSure, Alfa Scientific Designs, Thermo Fisher Scientific, Drägerwerk, LifeLoc, Omega Laboratories, Premier Biotech, Intoximeters, Sciteck Inc., Synens SAS, AccuSource Inc., and Creative Diagnostics. The development of innovative products is a key trend gaining popularity in the drug screening market. Major companies operating in the drug screening market are focusing on providing innovative products to meet fast-growing industry demand and strengthen their market position. Additionally, due to COVID, there was a sudden change in the drug screening approach, which changed the screening methodologies and pushed the innovation and new product development by companies. Companies are striving to develop new products such as a new drug test that is more effective and can be widely used by laboratories. For instance,in November 2020, Axion BioSystems, a US-based life science company, launched the Maestro ZHT high-throughput screening technology, utilizing their knowledge of live-cell equipment to give drug discovery and development a unique perspective. The Maestro ZHT tackles the challenges of finding and evaluating new candidates, capturing complex biology with a straightforward assay, and minimizing cost, time, and the waste of priceless antibodies and cells with a simple, automated, real-time, live-cell assay. In January 2020, StemBioSys, Inc., a Texas-based company involved in the development, manufacturing and distribution of life science tools acquired a majority stake in CarTox, Inc. for an undisclosed amount. This acquisition is expected to boost the company’s product portfolio in the drug screening and drug toxicology sector and contribute to its strategy to expand its business presence across the globe. CarTox, Inc. is a Michigan-based developer and manufacturer of drug screening and drug toxicology solutions. North America was the largest region in the drug screening market in 2022. Asia-Pacific is expected to be the fastest-growing region in the drug screening market during the forecast period. The regions covered in the drug screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The drug screening market consists of sales of testing kits, reagents, and other supplies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drug screening market research report is one of a series of new reports from The Business Research Company that provides drug screening market statistics, including drug screening industry global market size, regional shares, competitors with a drug screening market share, detailed drug screening market segments, market trends and opportunities, and any further data you may need to thrive in the drug screening industry. This drug screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prenatal testing and newborn screening tests are diagnostic tests to detect any possible birth defects that may be there in the baby. These are useful in determining the health of the baby. The main diagnostic types of prenatal testing and newborn screening are non-invasive and invasive. Invasive diagnostic testing necessitates puncturing the skin or invading the body. A few examples include blood testing, biopsies, and colonoscopies. The different technologies include screening technology, diagnostic technology and is used in various sectors such as hospitals, and diagnostic centres. The global prenatal testing & newborn screening market is segmented - 1) By Diagnostic Type: Non-Invasive, Invasive 2) By Technology: Screening Technology, Diagnostic Technology 3) By End user: Hospitals, Diagnostic centers The global prenatal testing & newborn screening market size grew from $5.04 billion in 2022 to $5.65 billion in 2023 at a compound annual growth rate (CAGR) of 12.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The prenatal testing & newborn screening market size is expected to grow from $8.87 billion in 2027 at a CAGR of 11.9%. The high prevalence of genetic diseases in infants contributed to the growth of the prenatal testing & newborn screening market. According to the World Health Organization, genetic disease includes diseases such as Thalassemia, Sickle Cell Anaemia, Haemophilia, Cystic Fibrosis, Tay Sachs disease, Fragile X Syndrome, Huntington’s disease. The sickle cell anaemia is one of the genetic diseases that affects millions throughout the world, and the disease is particularly common among people whose ancestors are from Africa, America, Cuba, Central America, Saudi Arabia, and India. According to data published in 2020 by the Centres for Disease Control and Prevention, a national public health agency of the United States, 5,568 babies were affected by Trisomy 21 (Down syndrome), 1,187 babies were affected by Trisomy 18 (Edwards syndrome), and 531 babies were affected by Trisomy 13 (Patau syndrome). The high prevalence of genetic diseases in infants boosted the demand for growth of the prenatal testing and newborn screening market. Major players in the prenatal testing & newborn screening market are PerkinElmer, Progenity, Laboratory Corporation of America Holdings (Sequenom), Natera, Invitae, Centogene, Cradle Genomics, Roche Diagnostics, Quest Diagnostics and Baebies. Growth of the prenatal testing & newborn screening market may be hampered by the relatively low healthcare access in most developing countries, compared to the developed nations. For instance, in India, there were only about 1.9 million hospital beds for 1.33 billion people, as of 2020. Low access to healthcare services and the lack of sufficient hospitals and healthcare professionals harmed market growth in many developing nations. Moreover, low disposable income in many countries further lowers the access to healthcare services, thus negatively hampering the growth of the prenatal testing & newborn screening market. The use of machine learning and artificial intelligence is gradually gaining popularity in the prenatal testing & newborn screening market. Artificial intelligence (AI) is the simulation of human intelligence in machines. Machine learning is a part of AI. Machine learning and AI help companies in the prenatal testing & newborn screening market to conduct a detailed analysis of all relevant data, provide insights about different diseases, and offer a more accurate evaluation of tissue samples. For instance, In September 2021, Sema4, a US-based AI-driven genomic and clinical data intelligence platform company, launched Sema4 Elements. Sema4 Elements are genetic solutions that are information-driven, digital tools for patients and providers, and services that let doctors manage patients holistically throughout their journeys with reproductive and generational health, using artificial intelligence. In March 2020, Thermo Fisher Scientific Inc. announced its decision to acquire Qiagen for $11.5 billion. Thermo Fisher has a specialty diagnostics capability, that includes allergy, autoimmunity, transplant diagnostics, and oncology testing. The acquisition is expected to complement Thermo Fisher’s genetic analysis and bioscience capabilities. Qiagen is a Germany-based genetic tester that was founded in 1984 and operates more than 35 offices in over 25 countries. North America was the largest region in the prenatal testing & newborn screening market in 2022. Western Europe was the second largest region in the global prenatal testing and newborn screening market share. The regions covered in the global prenatal testing and newborn screening tests market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the prenatal testing & newborn screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The prenatal testing & newborn screening market includes revenues earned by entities by providing blood test services, hearing test services, CCHD screening tests, and non-invasive tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The prenatal testing & newborn screening market research report is one of a series of new reports from The Business Research Company that provides prenatal testing & newborn screening market statistics, including prenatal testing & newborn screening industry global market size, regional shares, competitors with prenatal testing & newborn screening market share, detailed prenatal testing & newborn screening market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal testing and newborn screening tests industry. This prenatal testing and newborn screening tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Population health management refers to the process of improving the clinical health outcomes of a defined group of individuals through patient engagement and improved care coordination, and is supported by financial and care models. Population health management is used to improve the health outcomes of a group by identifying and monitoring patients. The main components of the population health management market include software and services. Software healthcare management refers to the use of software solutions to facilitate data across healthcare IT systems to improve operational efficiency and promote care delivery. The mode of delivery of population health management solutions includes on-premise and cloud-based. The various end-users include providers, payers, and other end-users. The global population health management market is segmented - 1) By Component: Software, Service 2) By Mode Of Delivery: On Premise, Cloud-Based 3) By End-User: Providers, Payers, Other End-Users The global population health management market size grew from $39.06 billion in 2022 to $47.23 billion in 2023 at a compound annual growth rate (CAGR) of 20.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global population health management market size is expected to grow to $99.75 billion in 2027 at a CAGR of 20.5%. The rising demand for solutions supporting value-based care delivery by healthcare shareholders is expected to propel the growth of the population health management market going forward. Value-based healthcare is a healthcare delivery framework that encourages healthcare providers to focus on the quality of services rendered as opposed to quantity. Value-based care delivery helps in reducing errors by enhancing workflows and interoperability, and lowers costs while increasing patient satisfaction, allowing executives to monitor and manage care. According to the Healthcare Payment Learning and Action Networks, a US-based group of public and private health care leaders’ APM measurement report, 40.9% of US healthcare payments came from value-based reimbursement models in 2020, which is a 2.7% increase over the 2019 rates. Thus, the rising demand for solutions supporting value-based care delivery by healthcare shareholders is driving the population health management market. Major players in the population health management market are Allscripts Healthcare LLC, Arcadia, Athenahealth Inc., Citra Health Solutions, Conifer Health Solutions, Cotiviti Inc., Deloitte Touche Tohmatsu Limited, eClinicalWorks, Enli Health Intelligence, Epic Systems Corporation, Evolent Health Inc., Forward Health Group, Koninklijke Philips, Lightbeam Health Solutions, Lumeris Inc., McKesson Corporation, MEDecision Inc., NextGen Healthcare Inc., Optum Inc., Orion Health, IBM Corporation, Accenture plc, Advisory Board, GE Healthcare (General Electric Company), Persivia Inc., RedBrick Health Corporation, Verscend Technologies Inc., and Welltok Inc. Product innovation is a key trend gaining popularity in the population health management market. Major companies operating in population health management are looking for new product development to strengthen their position in the population health management market. For instance, in October 2021, Verana Health, a US-based clinical database provider operating in the population health management market, launched VeraQ, a population health data engine. VeraQ converts unfiltered, raw healthcare data into a unique and actionable real-world data asset, Q data, from which business insights and clinical research can be derived. In April 2021, Cerner Corporation, a US-based healthcare information technology solutions, services, devices, and hardware provider, acquired Kantar Health for an amount of $375 million. Cerner’s real-world data and technology combined with Kantar Health’s rich life sciences expertise is expected to accelerate innovation in life sciences research and improve patient outcomes. Kantar Health is a US-based provider of data, analytics, and research to the life sciences industry, operating in the population health management market. North America was the largest region in the population health management market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the population health management market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the population health management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The population health management market includes revenues earned by entities care integration, care coordination, patient engagement, data analytics and health information technology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung cancer diagnosis and screening refers to using examinations and techniques to discover and identify lung cancer in people with the goal of early detection and precise diagnosis for efficient treatment planning. It is commonly used to treat squamous cell carcinomas, adenocarcinoma, and large cell carcinoma. The main products of lung cancer diagnostics and screening are instruments, consumables, and accessories. An instrument refers to products that are used to read or analyze the results of a diagnostic product, and process samples for a diagnostic product. The various tests include biomarkers tests, imaging tests, biopsy, blood tests, and others used for various cancer types such as non-small cell lung cancer, and small cell lung cancer. These are used by various end-users such as hospitals, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others. The global lung cancer diagnostic and screening market is segmented - 1) By Product: Instruments, Consumables And Accessories 2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests 3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer 4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users The global lung cancer diagnostic and screening market size is expected to grow from $1.91 billion in 2022 to $2.11 billion in 2023 at a compound annual growth rate (CAGR) of 10.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of lung cancer diagnostic and screening market is expected to reach $3.02 billion in 2027 at a CAGR of 9.4%. The increasing prevalence of lung cancer is expected to propel the growth of the lung cancer diagnostic and screening market going forward. Lung cancer is a malignant disease with symptoms such as coughing, chest pain, and difficulty breathing that is defined by the unchecked proliferation of abnormal cells in the lung tissues. Lung cancer diagnosis and screening help lung cancer patients early diagnose the disease with various tests, including an incisional biopsy and a bronchoscopy. For instance, in January 2023, according to the American Cancer Society, a US-based government organization, in the United States, there were approximately 238,340 new cases of lung cancer (117,550 in men and 120,790 in women). Further, there were reportedly 127,070 deaths from lung cancer (67,160 in men and 59,910 in women). Therefore, the rise in the prevalence of lung cancer is driving the growth of the lung cancer diagnostic and screening market. Major players in the lung cancer diagnostic and screening market are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories Inc., Medtronic Plc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Eon Health Inc., OncimmuneHoldings Plc, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, and iDNA. Technological innovations are a key trend gaining popularity in the lung cancer diagnostics and screening market. Major companies operating in the lung cancer diagnostics and screening market are introducing innovative technologies to sustain their position in the market. For instance, in December 2021, Auris Health, a US-based robotic medical company, introduced the MONARCH Robotic-Assisted Bronchoscopy procedure, the first MONARCH procedure. This procedure allows physicians to accurately diagnose small and hard-to-reach lung nodules, which enables biopsy for early diagnosis and treatment of lung disease. In January 2022, RadNet Inc., a US-based radiology company, acquired Aidence BV for an undisclosed amount. The acquisition is expected to enhance RadNet Inc.'s leadership in developing and deploying AI to improve patient care and health and accelerate growth and innovation pipeline to provide automated and integrated AI oncology solutions for clinicians. Aidence BV is a Netherlands-based healthcare technology company focusing on clinical solutions for lung cancer screening and pulmonary nodule treatment. North America was the largest region in the lung cancer diagnostic and screening market in 2022. The regions covered in lung cancer diagnosis and screening report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lung cancer diagnosis and screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The lung cancer diagnosis and screening market consists of revenues earned by entities by providing positron emission tomography (PET) scanners, and bronchoscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer diagnosis and screening market also includes sales of products such as liquid biopsy kits, molecular testing kits, and biopsy tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The lung cancer diagnostics and screening market research report are one of a series of new reports from The Business Research Company that provides lung cancer diagnostics and screening market statistics, including lung cancer diagnostics and screening industry global market size, regional shares, competitors with a lung cancer diagnostics and screening market share, detailed lung cancer diagnostics and screening market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer diagnostics and screening industry. This lung cancer diagnostics and screening market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.